High hERG1 expression in advanced melanoma.

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Cutaneous melanoma is a deadly skin cancer, with lesion thickness being a key prognostic factor.
• Prognosis is generally good for thin melanomas (≤1 mm) and poor for thicker lesions, but exceptions occur.
• The hERG1 potassium channel is often overexpressed in various cancers.

Purpose of the Study:

• To investigate the expression of the hERG1 protein in different types of cutaneous melanocytic lesions.
• To determine if hERG1 expression correlates with melanoma thickness and metastatic potential.
• To evaluate hERG1 as a potential biomarker for aggressive melanoma.

Main Methods:

• Immunohistochemistry was used to analyze hERG1 protein expression.
• Archival samples included typical nevi, atypical nevi, thin melanomas (≤1 mm), thick melanomas (>4 mm), and melanoma metastases.
• An hERG1-specific antibody was employed for the analysis.

Main Results:

• High levels of hERG1 expression were observed in thick melanomas (>4 mm) and melanoma metastases.
• Significantly lower hERG1 expression was detected in thin melanomas (<1 mm) and benign melanocytic nevi (typical and atypical).

Conclusions:

• hERG1 expression levels differ significantly between benign, thin melanoma, and aggressive melanoma lesions.
• hERG1 shows potential as a novel candidate biomarker for identifying aggressive cutaneous melanoma.
• Further research is warranted to validate hERG1's role in melanoma prognosis and treatment.